Heparin (Heparin sodium) 5 ampoules
Release Form:
p-r d/v/v and p/c introduction of 25 thousand ME/5 ml: Amp. 5 or 150 pcs.
Description:
The solution for in/in and p/c introduction of 1 ml 1 amp.
sodium heparin 5 thousand ME 25 thousand ME
5 ml ampoules (5) - packaging contour plastic (1) - pack cardboard.
5 ml ampoules (5) - packaging contour plastic (30) - cardboard boxes.
ATX codes
B01AB01 Heparin
Pharmacological groups / Group membership:
Direct-action anticoagulant - mediummolecular geparin
Active substance:
sodium heparin
Pharmacy Group:
Direct Action Anticoagulant
Pharmaceuticals
Direct-action anticoagulant, belongs to a group of mediumolecular heparins. In the plasma of blood activates antitrombin III, accelerating its anti-rotating action. Breaks the protrombin transition into trombin, depresses the activity of trombin and the activated X factor, to some extent reduces the aggregation of platelets.
For non-partitioned standard heparin, the ratio of anti-aggregate activity (anti-factor Xa) to anti-coagulant activity (ACTV) is 1:1.
Increases the kidney blood flow; increases the resistance of the brain's vessels, reduces the activity of brain hyaluronidase, activates lipoproteinlipase and has a hypolypdidism effect. Reduces the activity of the surfactant in the lungs, suppresses excessive synthesis of aldosterone in the cortex of the adrenaline, binds adrenaline, modulates the ovarian reaction to hormonal stimuli, increases the activity of the paragormone. Interaction with enzymes can increase the activity of thyrosihydroxylase of the brain, pepsinogen, DNA-polymerase and reduce the activity of myozine ATFaza, piryvatkinase, RNA polymerase, pease It's.
There are data on the presence of immunodepressive activity in the heparin.
In patients with IBS (in combination with acetylsalicialic acid) reduces the risk of development of acute trombosis of coronary arteries, myocardial heart attack and sudden death. Reduces the frequency of repeated heart attacks and the mortality of patients who have suffered myocardial heart attack. In high doses it is effective for thromboembolyas of the pulmonary artery and venous trombosis, in small - for prevention of venous thromboemboly, including after surgical operations.
When in/in the injection the blood reduction is slowed almost immediately, at v/m - after 15-30 min, at p/k - after 20-60 min, after inhalation of maximum effect - after day; The duration of the anticoagulant action - 4-5, 6, 8 hours and 1-2 weeks, respectively, the therapeutic effect - prevention of thrombosis - lasts much longer. Deficiency of antitrombin III in plasma or trombosis can reduce
Testimonials:
- Prevention and therapy: deep veins thrombosis, pulmonary artery thromboemboly (including peripheral veins), coronary artery thrombosis, thrombophlebitis, unstable stenocardia, acute myocardial heart attack, flick arrhythmia (including emboly-accompanied arrhythmia), DWS-syndrome, microtrombosis prevention and therapy and microcirculation disorders, renal venal thrombosis hemolytic-uremic syndrome, mitral heart disease (thrombo-formation prevention), bacterial endocarditis, glomerulonephritis, wolf nefrit.
- Prevention of blood folding during operations using in-vitro methods of blood circulation, hemodialysis, hemosorption, peritonial dialysis, citapherosis, forced diuresis, rinsing venous catheters.
- Preparation of samples of untwisting blood for laboratory purposes and blood transfusion.
Method of application, course and dosage:
Individual, depending on the medicinal form used, indications, clinical situation and age of the patient.
Drug Interaction:
Heparin's anti-rotating effect is intensified with the simultaneous use of anti-coagulants, anti-aggregators and NPWS.
Alkaloids of spory, tyroxin, tetracyclin, antihistamine, as well as nicotine reduce the effect of heparin.
Use in pregnancy and breastfeeding
Use during pregnancy is possible only on strict grounds, under careful medical control.
Contraindications: threatening miscarriage, childbirth (including recent).
It may be used during breastfeeding on the basis of the indication.
Side Action:
On the side of the blood screwdriver system: LCD and urinary tract bleeding, injection in areas under pressure, from operating wounds, as well as hematuria, thrombocytopenia in other organs are possible.
From the digestive system: nausea, reduced appetite, vomiting, diarrhea, increased activity of liver transaminaz.
Allergic reactions: leather hyperemia, drug Heparin fever, nettle, rhinitis, skin itching and heat sensation in the soles, bronchospasm, collapse, anaphylactic shock.
On the side of the blood screwdriver system: Thrombocytopenia (can be severe up to death) followed by skin necrosis, arterial trombosis, accompanied by the development of gangrene, myocardial heart attack, stroke.
n the side of the bone and muscle system: For long-term application - osteoporosis, spontaneous fractures, calcification of soft tissues.
Local reactions: irritation, pain, hyperemia, hematoma and ulcer in the place of injection.
Others: transient alopecia, hypoaldosteronism.
Contraindications to use:
Bleedings, diseases associated with the disruption of blood folding processes, suspicion of intra-cerebral hemorrhage, aneurysm of the brain vessels, hemorrhagic stroke, spreading aorta aneurysm, antiphospholipid syndrome, malignant arterial hypertension, substrate bacterial endocarditis, erosive-ulcer lesions, severe damage to liver parenchyms, cirrhosis from the liver varicose ventilation enlargement esophagus, malignant liver neoplasm, shock conditions, recent surgical interventions in front of the eyes, brain, prostate, liver and gastrointestinal tract, post-spinal cord puncture, menstruation Shush, childbirth (including recent ones), increased sensitivity to heparin.
Special Instructions:
Caution to apply in patients suffering from polyvalent allergies (including bronchial asthma), arterial hypertension, dental manipulation, diabetes mellitus, endocardide, pericardide, if present Intrauterine contraception, active tuberculosis, radiation therapy, liver failure, chronic renal failure, in elderly patients (over 60, especially women).
It is not recommended in/m introduction of heparin due to the possibility of hematoma development, as well as in/out introduction of other drugs Heparin against the background of heparin treatment.
It is used with care externally in hemorrhages and conditions of high blood flow, thrombocytopenia.
During the treatment of heparin it is necessary to control the indicators of blood folding.
Only a physiological solution is used to breed a heparin.
In the case of the development of severe thrombocytopenia (reduction of platelet by 2 times the original number or below 100,000/mkl), the use of heparin must be stopped urgently.
The risk of bleeding can be minimized by careful assessment of contraindications, regular laboratory monitoring of blood folding and adequate dosage
Application for kidney disorders
It is used according to the testimony of patients with severe kidney diseases.
Application for liver disorders
Contraindications: Severe damage to liver parenchyms, liver cirrhosis with varicose extension of esophagus veins, malignant liver neoplasm.
Application of elderly patients
Carefully used in elderly patients (over 60, especially women).
Application of children
It is possible to use in children according to the testimony.
Nozology (ICD codes)
Hemolytic-Uremic Syndrome
Disseminated Intra-Vascular Collapse [Defibration Syndrome]
Unstable Stenocardium
Acute myocardial heart attack
Lung embolism
Acute endocarditis unspecified
Mitral (valve) insufficiency
Firmware and trembling atriums
Embolia and artery thrombosis
Flybit and Trombophlebit
Embolia and thrombosis of other veins
Acute jade syndrome (acute glomerulonephritis)
Chronic Jade Syndrome
Glomerulary lesions for system diseases of the connective tissue
Preparatory procedures for follow-up treatment or examination not classified in other headings
